journal
MENU ▼
Read by QxMD icon Read
search

Clinical Colorectal Cancer

journal
https://www.readbyqxmd.com/read/29661621/predictive-nomogram-for-recurrence-of-stage-i-colorectal-cancer-after-curative-resection
#1
Chan Kim, Woo Ram Kim, Ki-Yeol Kim, Hong Jae Chon, Seung Hoon Beom, Hyojoong Kim, Minkyu Jung, Sang Joon Shin, Nam Kyu Kim, Joong Bae Ahn
BACKGROUND: Patients with stage I colorectal cancer (CRC) have excellent prognosis after curative surgery. However, approximately 5% to 10% of patients experience recurrence and have a poor prognosis. Because the incidence of stage I CRC is increasing with active screening programs worldwide, a more accurate and easy-to-use predictive tool for recurrence is becoming more important. This study aimed to develop a predictive nomogram for recurrence in stage I CRC. PATIENTS AND METHODS: A total of 1538 patients who underwent curative surgery for stage I CRC were enrolled...
March 29, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29678514/effect-of-neoadjuvant-therapy-and-rectal-surgery-on-health-related-quality-of-life-in-patients-with-rectal-cancer-during-the-first-2-years-after-diagnosis
#2
Alice M Couwenberg, Johannes P M Burbach, Wilhelmina M U van Grevenstein, Anke B Smits, Esther C J Consten, Anandi H W Schiphorst, Niels A T Wijffels, Joost T Heikens, Martijn P W Intven, Helena M Verkooijen
INTRODUCTION: Rectal cancer surgery with neoadjuvant therapy is associated with substantial morbidity. The present study describes the course of quality of life (QOL) in rectal cancer patients in the first 2 years after the start of treatment. PATIENTS AND METHODS: We performed a prospective study within a colorectal cancer cohort including rectal cancer patients who were referred for neoadjuvant chemoradiation or short-course radiotherapy and underwent rectal surgery...
March 21, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29650416/effect-of-comorbidities-in-stage-ii-iii-colorectal-cancer-patients-treated-with-surgery-and-neoadjuvant-adjuvant-chemotherapy-a-single-center-observational-study
#3
Marina Baretti, Lorenza Rimassa, Nicola Personeni, Laura Giordano, Maria Chiara Tronconi, Tiziana Pressiani, Silvia Bozzarelli, Armando Santoro
BACKGROUND: Comorbidity has a detrimental effect on cancer survival, however, it is difficult to disentangle its direct effect from its influence on treatment choice. In this study we assessed the effect of comorbidity on survival in patients who received standard treatment for resected stage II and III colorectal cancer (CRC). PATIENTS AND METHODS: In total, 230 CRC patients, 68 rectal (29.6%) and 162 colon cancer (70.4%) treated with surgical resection and neoadjuvant/adjuvant chemotherapy from December 2002 to December 2009 at Humanitas Cancer Center were retrospectively reviewed...
March 21, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29636300/prognostic-value-of-acvrl1-expression-in-metastatic-colorectal-cancer-patients-receiving-first-line-chemotherapy-with-bevacizumab-results-from-the-triplet-plus-bevacizumab-tribe-study
#4
Diana L Hanna, Fotios Loupakis, Dongyun Yang, Chiara Cremolini, Marta Schirripa, Meng Li, Satoshi Matsusaka, Martin D Berger, Yuji Miyamoto, Wu Zhang, Yan Ning, Carlotta Antoniotti, Lisa Salvatore, Miriana Moran, Gary Zeger, Stephanie H Astrow, Alfredo Falcone, Heinz-Josef Lenz
BACKGROUND: No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorectal cancer patients. ACVRL1 (activin receptor like-protein 1) encodes for ALK1, a member of the transforming growth factor-β receptor family, which directs pathologic angiogenesis. We examined the intratumoral expression of ACVRL1 and other angiogenesis pathway-related genes to identify molecular markers in the TRIBE study. MATERIALS AND METHODS: Of 503 randomized patients, 228 had sufficient tissue for analysis...
March 14, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29615310/meta-analysis-of-modified-folfirinox-regimens-for-patients-with-metastatic-pancreatic-cancer
#5
Pedro Luiz Serrano Usón Junior, Edna Terezinha Rother, Fernando Cotait Maluf, Diogo Diniz Gomes Bugano
BACKGROUND: We performed a meta-analysis of previous reports evaluating the effect of mFIO (modified FOLFIRINOX; leucovorin, 5-fluorouracil, irinotecan, oxaliplatin) regimens in advanced pancreatic cancer. MATERIALS AND METHODS: We performed a meta-analysis of reported studies in PubMed, Scopus, and Web of Science (1950-2016) in December 2016. The inclusion criteria were randomized trials, prospective or retrospective cohorts, patients with metastatic pancreatic adenocarcinoma, the use of mFIO or FOLFIRINOX (FIO) chemotherapy, and available information for ≥ 1 efficacy endpoint (response rate, progression-free survival, and/or overall survival)...
March 14, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29661620/tolerability-safety-and-outcomes-of-neoadjuvant-chemoradiotherapy-with-capecitabine-for-patients-aged-%C3%A2-70-years-with-locally-advanced-rectal-cancer
#6
Lotte Jacobs, Ellen van der Vlies, Daan Ten Bokkel Huinink, Haiko Bloemendal, Martijn Intven, Anke B Smits, Bas L A M Weusten, Peter D Siersema, Niels van Lelyveld, Maartje Los
INTRODUCTION: In studies of colorectal cancer, the elderly have been frequently underrepresented because comorbid conditions and functional status often lead to study exclusion. For elderly patients with an indication for neoadjuvant chemoradiotherapy (nCRT), physicians usually decide using clinical factors whether nCRT should be offered. The aim of the present retrospective study was to assess the tolerability of nCRT with capecitabine and the surgical outcomes in patients aged ≥ 70 years with locally advanced rectal cancer...
March 8, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29653857/a-randomized-phase-ii-study-of-folfox6-bevacizumab-with-or-without-pelareorep-in-patients-with-metastatic-colorectal-cancer-ind-210-a-canadian-cancer-trials-group-trial
#7
Derek J Jonker, Patricia A Tang, Hagen Kennecke, Stephen A Welch, M Christine Cripps, Timothy Asmis, Haji Chalchal, Anna Tomiak, Howard Lim, Yoo-Joung Ko, Eric X Chen, Thierry Alcindor, John R Goffin, Grzegorz J Korpanty, Harriet Feilotter, Ming S Tsao, Ashley Theis, Dongsheng Tu, Lesley Seymour
BACKGROUND: Oncolytic reovirus pelareorep might preferentially infect and destroy rat sarcoma (RAS)-activated cells, and has preclinical and early clinical activity against colorectal cancer (CRC). PATIENTS AND METHODS: After a 6-patient safety run-in, 103 patients with metastatic CRC were randomly assigned to standard first-line leucovorin/5-FU/oxaliplatin (FOLFOX6)/bevacizumab (FOLFOX/BEV) every 2 weeks with (n = 51) or without (n = 52) pelareorep 3 × 1010 tissue culture infective dose 50 on days 1 to 5 (cycles 1, 2, 4, and alternate cycles thereafter)...
March 8, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29631907/efficacy-and-tolerability-of-second-line-nab-paclitaxel-and-gemcitabine-after-failure-of-first-line-folfirinox-for-advanced-pancreas-cancer-a-single-institution-experience
#8
Hanbo Zhang, Curtis Kellett, Pascal Lambert, Christina A Kim
BACKGROUND: Advanced pancreatic cancer (APC) has a poor prognosis. Current first-line chemotherapy options include FOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin), NG (nab-paclitaxel, gemcitabine), and GEM (gemcitabine) alone. The optimal second-line regimen is unclear. For patients with disease progression with FOLFIRINOX who have a good performance status, NG might be a reasonable second-line option. PATIENTS AND METHODS: Patients in whom APC was diagnosed from 2012 to 2016 who underwent chemotherapy at CancerCare Manitoba were identified from the Manitoba Cancer Registry...
March 8, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29627309/effect-of-primary-tumor-location-on-second-or-later-line-treatment-outcomes-in-patients-with-ras-wild-type-metastatic-colorectal-cancer-and-all-treatment-lines-in-patients-with-ras-mutations-in-four-randomized-panitumumab-studies
#9
Nele Boeckx, Reija Koukakis, Ken Op de Beeck, Christian Rolfo, Guy Van Camp, Salvatore Siena, Josep Tabernero, Jean-Yves Douillard, Thierry André, Marc Peeters
BACKGROUND: The primary tumor location has a prognostic impact in metastatic colorectal cancer (mCRC). We report the results from retrospective analyses assessing the effect of tumor location on prognosis and efficacy of second- and later-line panitumumab treatment in patients with RAS wild-type (WT) mCRC and on prognosis in all lines of treatment in patients with RAS mutant (MT) mCRC. PATIENTS AND METHODS: RAS WT data (n = 483) from 2 randomized phase III panitumumab trials (ClinicalTrials...
March 8, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29605592/aflibercept-plus-folfiri-in-the-real-life-setting-safety-and-quality-of-life-data-from-the-italian-patient-cohort-of-the-aflibercept-safety-and-quality-of-life-program-study
#10
Alessandro Pastorino, Maria Di Bartolomeo, Evaristo Maiello, Vincenzo Iaffaioli, Libero Ciuffreda, Gianpiero Fasola, Francesco Di Costanzo, Giovanni Luca Frassineti, Paolo Marchetti, Carlotta Antoniotti, Francesco Leone, Alberto Zaniboni, Giuseppe Aprile, Chiara Zilocchi, Alberto Sobrero, Roberto Bordonaro
BACKGROUND: Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs. placebo in combination with irinotecan and 5-fluorouracil in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin-based regimen) trial. No quality-of-life assessment was performed in VELOUR; therefore, the ASQoP (Aflibercept Safety and Quality-of-Life Program) trial was designed to capture the safety and health-related quality of life (HRQL)...
March 8, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29525524/pattern-and-management-of-recurrence-of-mid-low-rectal-cancer-after-neoadjuvant-intensity-modulated-radiotherapy-single-center-results-of-687-cases
#11
Ai-Wen Wu, Yong Cai, Yong-Heng Li, Lin Wang, Zhong-Wu Li, Ying-Shi Sun, Jia-Fu Ji
BACKGROUND: The purpose of this study was to retrospectively analyze the pattern and the management of recurrence of rectal cancer treated with 22-fraction intensity-modulated radiation therapy (IMRT). PATIENTS AND METHODS: This study included patients who underwent IMRT with gross tumor volume of 50.6 Gy in 22 fractions with concurrent capecitabine treatment over a period of 30 days, after which the patients underwent total mesorectal excision at Peking University Cancer Hospital (2007-2015)...
March 7, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29678513/review-of-blood-based-colorectal-cancer-screening-how-far-are-circulating-cell-free-dna-methylation-markers-from-clinical-implementation
#12
REVIEW
Mai-Britt Worm Ørntoft
Colorectal cancer (CRC) is a leading cause of cancer related deaths worldwide, and late stages (III-IV) in particular have low 5-year survival rates. Stage shifting by CRC screening programs has proven effective by decreasing morbidity and mortality and in many countries national CRC screening programs have been implemented. Currently, European, Asian, and American authorities recommend screening for CRC using fecal occult blood testing, sigmoidoscopy, or colonoscopy. Because these approaches all have weaknesses (eg, poor compliance, high costs, test invasiveness), much effort has been put into the development of alternative screening approaches, many of which are blood-based...
March 2, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29576428/c-met-overexpression-in-colorectal-cancer-a-poor-prognostic-factor-for-survival
#13
Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park, Seung Tae Kim
INTRODUCTION: Increased mesenchymal-epithelial transition factor gene (c-MET) expression in several human malignancies is related to increased tumor progression and is a new potential drug target for several types of cancers. In the present study, we investigated the incidence of c-MET overexpression and its prognostic significance in patients with colorectal cancer (CRC). PATIENTS AND METHODS: We retrospectively reviewed the data from 255 stage IV CRC patients who had results from a c-MET immunohistochemical test at Samsung Medical Center...
March 2, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29576426/a-pilot-study-of-apatinib-as-third-line-treatment-in-patients-with-heavily-treated-metastatic-colorectal-cancer
#14
Lijun Liang, Lei Wang, Panrong Zhu, Youyou Xia, Yun Qiao, Jiang Wu, Wei Zhuang, Jiayan Fei, Yixuan Wen, Xiaodong Jiang
BACKGROUND: Antiangiogenic therapy has shown improved clinical outcome in metastatic colorectal cancer (mCRC). After the failure of standard treatments, regorafenib and TAS-102 would be recommended for patients with mCRC, however, they have not been approved in China during this study period. PATIENTS AND METHODS: This pilot study aimed to assess the efficacy and safety of apatinib, a novel oral inhibitor targeting vascular endothelial growth factor receptor 2, as third-line treatment for patients with mCRC refractory to standard therapies...
March 2, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29606345/gene-polymorphisms-in-the-ccl5-ccr5-pathway-as-a-genetic-biomarker-for-outcome-and-hand-foot-skin-reaction-in-metastatic-colorectal-cancer-patients-treated-with-regorafenib
#15
Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Chiara Cremolini, Carlotta Antoniotti, Beatrice Borelli, Tetsuo Mashima, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Roel Gopez, Afsaneh Barzi, Sara Lonardi, Toshiharu Yamaguchi, Alfredo Falcone, Fotios Loupakis, Heinz-Josef Lenz
BACKGROUND: The C-C motif chemokine ligand 5/C-C motif chemokine receptor 5 (CCL5/CCR5) pathway has been shown to induce endothelial progenitor cell migration, resulting in increased vascular endothelial growth factor A expression. We hypothesized that genetic polymorphisms in the CCL5/CCR5 pathway predict efficacy and toxicity in patients with metastatic colorectal cancer (mCRC) treated with regorafenib. PATIENTS AND METHODS: We analyzed genomic DNA extracted from 229 tumor samples from 2 different cohorts of patients who received regorafenib: an evaluation cohort of 79 Japanese patients and a validation cohort of 150 Italian patients...
February 27, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29580650/significance-of-pitx2-promoter-methylation-in-colorectal-carcinoma-prognosis
#16
Alexander Semaan, Barbara Uhl, Vittorio Branchi, Philipp Lingohr, Friedrich Bootz, Glen Kristiansen, Jörg C Kalff, Hanno Matthaei, Dimitrios Pantelis, Dimo Dietrich
BACKGROUND: New treatment modalities and a growing understanding of the complex genetic tumor landscape have improved the outcome of colorectal cancer (CRC) patients. Nonetheless, more individualized treatment regimens, taking individual tumor characteristics into account, have been recently postulated and prognostic biomarkers are needed. We therefore evaluated the prognostic potential of paired-like homeodomain transcription factor 2 (PITX2) promoter methylation in CRC patients. MATERIALS AND METHODS: Data of 2 independent cohorts were investigated...
February 23, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29550155/regorafenib-or-trifluridine-tipiracil-in-refractory-metastatic-colorectal-cancer-a-perspective-on-the-basis-of-pharmacological-costs
#17
LETTER
Jacopo Giuliani, Andrea Bonetti
No abstract text is available yet for this article.
February 23, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29605591/mutation-and-methylation-analysis-of-circulating-tumor-dna-can-be-used-for-follow-up-of-metastatic-colorectal-cancer-patients
#18
Nele Boeckx, Ken Op de Beeck, Matthias Beyens, Vanessa Deschoolmeester, Christophe Hermans, Peggy De Clercq, Sonia Garrigou, Corinne Normand, Els Monsaert, Konstantinos Papadimitriou, Pierre Laurent-Puig, Patrick Pauwels, Guy Van Camp, Valerie Taly, Marc Peeters
BACKGROUND: Targeted therapies, although contributing to survival improvement in metastatic colorectal cancer (mCRC), are expensive and may cause adverse effects. Therefore, confirming that patients are responding to these therapies is extremely important. Currently, follow-up is performed using radiographic evaluation, which has its limitations. Liquid biopsies, reflecting real-time tumor characteristics, hold great potential in monitoring tumor disease. PATIENTS AND METHODS: Blood samples were collected at different time points during treatment of 24 mCRC patients...
February 22, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29548772/efficacy-and-safety-of-regorafenib-with-2-1-schedule-for-patients-%C3%A2-75-years-with-metastatic-colorectal-cancer-mcrc-after-failure-of-2-lines-of-chemotherapy
#19
Roberto Petrioli, Martina Chirra, Luciana Messuti, Anna Ida Fiaschi, Vinno Savelli, Ignazio Martellucci, Edoardo Francini
BACKGROUND: In the CORRECT (patients with metastatic COloRectal Cancer treated with REgorafenib or plaCebo after failure of standard Therapy) trial, regorafenib was proven to extend survival of patients with metastatic colorectal cancer (mCRC) that progressed after all available therapies. Grade 3 to 4 toxicity occurred in 54% of patients, and data on the activity and tolerability of regorafenib in elderly patients were scarce. The aim of this study was to evaluate the efficacy and safety of an alternative schedule, 2-week-on treatment and 1 week-off (2/1 schedule), of regorafenib for elderly patients with mCRC...
February 21, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29572136/addressing-racial-disparity-in-colorectal-cancer-screening-with-ct-colonography-experience-in-an-african-american-cohort
#20
Courtney C Moreno, Todd F Fibus, Elizabeth A Krupinski, David H Kim, Perry J Pickhardt
BACKGROUND: Incidence and mortality from colorectal cancer (CRC) are higher among African Americans where CRC screening rates lag behind non-Hispanic whites. The purpose of this investigation was to evaluate CT colonography (CTC) performance and outcome measures in an African-American cohort. MATERIALS AND METHODS: This study is an institutional review board-approved and Health Insurance Portability and Accountability Act-compliant study. Retrospective evaluation of the African-American cohort from the Atlanta VA Medical Center (Decatur, Georgia) CTC screening program...
February 20, 2018: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"